October 6, 2025 — San Francisco, USA – AstraZeneca announced a strategic collaboration and licensing agreement with Algen Biotechnologies, a U.S.-based biotech company specializing in AI-driven gene therapy discovery. The deal is valued at up to $555 million, combining an upfront payment and milestone-based development and commercialization incentives.
Under the agreement, AstraZeneca will leverage Algen’s proprietary AlgenBrain™ platform, an artificial intelligence–powered system for identifying and optimizing genetic targets, to develop novel gene therapies for immune-related diseases.
Photo by Testalize.me on Unsplash
This partnership underscores AstraZeneca’s continued investment in next-generation genetic medicine and its strategy to expand the company’s immunology pipeline through external innovation. For Algen Biotechnologies, the collaboration represents both a financial milestone and a validation of its AI-enabled therapeutic discovery approach.
Industry observers note that this deal reflects a growing trend among large pharmaceutical companies to engage with early-stage biotech innovators in the gene and cell therapy space, particularly those integrating computational biology and artificial intelligence to accelerate development timelines.
Photo by Ashraful Islam onUnsplash
Source: Reuters, “AstraZeneca signs up $555 million deal with US-based Algen to develop gene therapies,” October 6, 2025.
About Hillgene
Hillgene is a biotechnology company specializing in cell and gene therapy CDMO services, providing end-to-end solutions from process development to GMP manufacturing. Leveraging expertise in viral vector production, stable cell line generation, and immune cell expansion, Hillgene empowers global partners to accelerate preclinical and clinical translation. → Click to Learn More
86 198 5711 6962 
info@hillgene.com 
English
